The Acute Leukaemias:@0.703132:0.035749:0.914567:0.035749:0.914567:0.019993:0.703132:0.019993:0.008197:0.011738:0.012508:0.005330:0.014239:0.012450:0.011699:0.006523:0.012508:0.005330:0.008890:0.012508:0.011699:0.009660:0.013143:0.012508:0.018049:0.003848:0.013143:0.007466
TREATMENT APPROACHES:@0.983689:0.278245:0.983689:0.065272:0.955679:0.065272:0.955679:0.278245:0.000000:0.000000:0.000000:0.057096:-0.123230:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.375913
83:@0.955522:0.038184:0.976595:0.038184:0.976595:0.018587:0.955522:0.018587:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.679047:0.970015:0.915156:0.970015:0.915156:0.956010:0.679047:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
Clinical trials have shown that oral mainte-:@0.084242:0.096166:0.475113:0.096166:0.475113:0.080410:0.084242:0.080410:0.015452:0.003656:0.003656:0.011545:0.003656:0.012257:0.012950:0.003656:0.005984:0.006331:0.005600:0.003656:0.012950:0.003656:0.007274:0.005984:0.011545:0.012950:0.010468:0.012315:0.005984:0.007274:0.011545:0.012411:0.015798:0.011545:0.005984:0.006331:0.011545:0.012950:0.006331:0.005984:0.012411:0.005600:0.012950:0.003656:0.005984:0.017857:0.012950:0.003656:0.011545:0.006331:0.012315:0.006388
nance chemotherapy (methotrexate and :@0.084242:0.112385:0.480497:0.112385:0.480497:0.096629:0.084242:0.096629:0.011545:0.012950:0.011545:0.012257:0.012315:0.007428:0.012257:0.011545:0.012315:0.017857:0.012411:0.006331:0.011545:0.012315:0.005600:0.012950:0.012931:0.010122:0.007428:0.006908:0.017857:0.012315:0.006331:0.011545:0.012411:0.006331:0.005519:0.012315:0.009044:0.012950:0.006331:0.012315:0.007428:0.012950:0.011545:0.013181:0.005330
mercaptopurine) for two or three years :@0.084242:0.128604:0.480540:0.128604:0.480540:0.112848:0.084242:0.112848:0.017857:0.012315:0.005463:0.012257:0.012950:0.012931:0.006331:0.012411:0.012931:0.011507:0.005600:0.003656:0.011545:0.012315:0.006908:0.012219:0.005850:0.012411:0.005600:0.012219:0.006331:0.015798:0.012411:0.012219:0.012411:0.005600:0.012219:0.006331:0.011545:0.005521:0.012315:0.012315:0.012219:0.010122:0.012315:0.012950:0.005600:0.007470:0.005330
with periodic reinforcements with vincris-:@0.084242:0.144677:0.475167:0.144677:0.475167:0.128921:0.084242:0.128921:0.015798:0.003656:0.006331:0.011545:0.010737:0.012931:0.012315:0.005600:0.003656:0.012411:0.012989:0.003656:0.012257:0.010737:0.005521:0.012315:0.003656:0.011545:0.005850:0.012411:0.005463:0.012257:0.012315:0.017857:0.012315:0.011545:0.006331:0.007274:0.010737:0.015798:0.003656:0.006331:0.011545:0.010737:0.010468:0.003656:0.011545:0.012257:0.005600:0.003656:0.007274:0.006388
tine and prednisone leads to long-term, :@0.084242:0.160750:0.480507:0.160750:0.480507:0.144994:0.084242:0.144994:0.006331:0.003656:0.011545:0.012315:0.010930:0.012950:0.011545:0.012989:0.010930:0.012931:0.005519:0.012315:0.012989:0.011545:0.003656:0.007274:0.012411:0.011545:0.012315:0.010930:0.003656:0.012315:0.012950:0.012989:0.007274:0.010930:0.006331:0.012411:0.010930:0.003656:0.012411:0.011545:0.012758:0.006196:0.006331:0.012315:0.006131:0.017857:0.005328:0.005330
relapse-free survival in the majority of chil-:@0.084242:0.176824:0.475148:0.176824:0.475148:0.161068:0.084242:0.161068:0.005521:0.012315:0.003656:0.012950:0.012931:0.007274:0.012315:0.006196:0.005850:0.005521:0.012315:0.012315:0.007062:0.007274:0.011507:0.005600:0.010468:0.003656:0.010468:0.012950:0.003656:0.007062:0.003656:0.011545:0.007062:0.006331:0.011545:0.012315:0.007062:0.017857:0.012950:0.003714:0.012411:0.005600:0.003656:0.006331:0.010122:0.007062:0.012411:0.005850:0.007062:0.012257:0.011545:0.003656:0.003656:0.006388
dren and 35% of adults, depending on pre-:@0.084242:0.192897:0.475148:0.192897:0.475148:0.177141:0.084242:0.177141:0.012989:0.005521:0.012315:0.011545:0.004734:0.012950:0.011545:0.012989:0.004734:0.010468:0.010468:0.014720:0.004734:0.012411:0.005850:0.004734:0.012950:0.012989:0.011507:0.003656:0.006331:0.007274:0.005138:0.004734:0.012989:0.012315:0.012931:0.012315:0.011545:0.012989:0.003656:0.011545:0.012758:0.004734:0.012411:0.011545:0.004734:0.012931:0.005521:0.012315:0.006388
treatment risk factors and response to initial :@0.084242:0.208971:0.480494:0.208971:0.480494:0.193215:0.084242:0.193215:0.006331:0.005519:0.012315:0.012950:0.006331:0.017857:0.012315:0.011545:0.006331:0.004551:0.005600:0.003656:0.007274:0.009467:0.004551:0.005850:0.012950:0.012257:0.006331:0.012411:0.005600:0.007274:0.004551:0.012950:0.011545:0.012989:0.004551:0.005519:0.012315:0.007274:0.012931:0.012411:0.011545:0.007274:0.012315:0.004549:0.006331:0.012411:0.004549:0.003656:0.011545:0.003656:0.006331:0.003656:0.012950:0.003852:0.005330
therapy.:@0.084242:0.225044:0.161366:0.225044:0.161366:0.209288:0.084242:0.209288:0.006331:0.011545:0.012315:0.005600:0.012950:0.012931:0.010122:0.005330
11-15:@0.161166:0.219427:0.189302:0.219427:0.189302:0.210242:0.161166:0.210242:0.006103:0.006103:0.003612:0.006103:0.006215
 A group of interest are patients :@0.189199:0.225047:0.480543:0.225047:0.480543:0.209291:0.189199:0.209291:0.004830:0.014047:0.004830:0.012758:0.005519:0.012411:0.011507:0.012931:0.004830:0.012411:0.005850:0.004830:0.003656:0.011545:0.006331:0.012315:0.005519:0.012315:0.007274:0.006331:0.004830:0.012950:0.005521:0.012315:0.004830:0.012931:0.012950:0.006331:0.003656:0.012315:0.011545:0.006331:0.007470:0.005330
who develop the BCR-ABL (p190KD) muta-:@0.084251:0.241120:0.475160:0.241120:0.475160:0.225364:0.084251:0.225364:0.015798:0.011545:0.012411:0.005561:0.012989:0.012315:0.010468:0.012315:0.003656:0.012411:0.012931:0.005561:0.006331:0.011545:0.012315:0.005561:0.010853:0.015452:0.011488:0.006196:0.014047:0.010853:0.008698:0.005561:0.006908:0.012931:0.010468:0.010468:0.010468:0.011180:0.014124:0.006908:0.005561:0.017857:0.011507:0.006331:0.012950:0.006388
tion as they are highly responsive to the ty-:@0.084251:0.257194:0.475201:0.257194:0.475201:0.241438:0.084251:0.241438:0.006331:0.003656:0.012411:0.011545:0.005619:0.012950:0.007274:0.005609:0.006331:0.011545:0.012315:0.010122:0.005619:0.012950:0.005519:0.012315:0.005619:0.011545:0.003656:0.012758:0.011545:0.003656:0.010122:0.005619:0.005519:0.012315:0.007274:0.012931:0.012411:0.011545:0.007274:0.003656:0.010468:0.012315:0.005619:0.006331:0.012411:0.005609:0.006331:0.011545:0.012315:0.005609:0.006331:0.010122:0.006388
rosine kinase inhibition (TKI), typically more :@0.084251:0.273267:0.480485:0.273267:0.480485:0.257511:0.084251:0.257511:0.005521:0.012411:0.007274:0.003656:0.011545:0.012315:0.006754:0.009467:0.003656:0.011545:0.012950:0.007274:0.012315:0.006754:0.003656:0.011545:0.011545:0.003656:0.012931:0.003656:0.006331:0.003656:0.012411:0.011545:0.006754:0.006908:0.008005:0.011180:0.004156:0.006908:0.005138:0.006754:0.006331:0.010122:0.012931:0.003656:0.012257:0.012950:0.003656:0.003656:0.010122:0.006754:0.017857:0.012411:0.005521:0.012506:0.005330
often in the older population. TKIs (imatinib, :@0.084251:0.289340:0.480508:0.289340:0.480508:0.273584:0.084251:0.273584:0.012411:0.005850:0.006331:0.012315:0.011545:0.004868:0.003656:0.011545:0.004868:0.006331:0.011545:0.012315:0.004868:0.012411:0.003656:0.012989:0.012315:0.005600:0.004868:0.012931:0.012411:0.012931:0.011507:0.003656:0.012950:0.006331:0.003656:0.012411:0.011545:0.005138:0.004868:0.008005:0.011180:0.004156:0.007274:0.004868:0.006908:0.003656:0.017857:0.012950:0.006331:0.003656:0.011545:0.003656:0.012931:0.005328:0.005330
dasatinib) have shown to have clinical :@0.084251:0.305414:0.480456:0.305414:0.480456:0.289658:0.084251:0.289658:0.012989:0.012950:0.007274:0.012950:0.006331:0.003656:0.011545:0.003656:0.012931:0.006908:0.012796:0.011545:0.012950:0.010468:0.012315:0.012796:0.007274:0.011545:0.012411:0.015798:0.011545:0.012796:0.006331:0.012411:0.012796:0.011545:0.012950:0.010468:0.012315:0.012796:0.012257:0.003656:0.003656:0.011545:0.003656:0.012257:0.012950:0.003852:0.005330
activity as a single agent and led to high :@0.084251:0.321487:0.480525:0.321487:0.480525:0.305731:0.084251:0.305731:0.012950:0.012257:0.006331:0.003656:0.010468:0.003656:0.006331:0.010122:0.007505:0.012950:0.007274:0.007505:0.012950:0.007505:0.007274:0.003656:0.011545:0.012758:0.003656:0.012315:0.007495:0.012950:0.012758:0.012315:0.011545:0.006331:0.007505:0.012950:0.011545:0.012989:0.007495:0.003656:0.012315:0.012989:0.007505:0.006331:0.012411:0.007505:0.011545:0.003656:0.012758:0.011734:0.005330
responses with extended survival in elderly :@0.084251:0.337561:0.480479:0.337561:0.480479:0.321805:0.084251:0.321805:0.005521:0.012315:0.007274:0.012931:0.012411:0.011545:0.007274:0.012315:0.007274:0.006646:0.015798:0.003656:0.006331:0.011545:0.006648:0.012315:0.009044:0.006331:0.012315:0.011545:0.012989:0.012315:0.012989:0.006648:0.007274:0.011507:0.005600:0.010468:0.003656:0.010468:0.012950:0.003656:0.006648:0.003656:0.011545:0.006648:0.012315:0.003656:0.012989:0.012315:0.005600:0.003656:0.010316:0.005330
patients. Their inclusion is recommended :@0.084251:0.353634:0.480508:0.353634:0.480508:0.337878:0.084251:0.337878:0.012931:0.012950:0.006331:0.003656:0.012315:0.011545:0.006331:0.007274:0.005138:0.010583:0.008005:0.011545:0.012315:0.003656:0.005600:0.010583:0.003656:0.011545:0.012257:0.003656:0.011507:0.007274:0.003656:0.012411:0.011545:0.010583:0.003656:0.007274:0.010583:0.005521:0.012315:0.012257:0.012411:0.017857:0.017857:0.012315:0.011545:0.012989:0.012315:0.013181:0.005330
in  the  routine  treatment  of  children  and :@0.084251:0.369708:0.480521:0.369708:0.480521:0.353952:0.084251:0.353952:0.003656:0.011545:0.005330:0.004895:0.006331:0.011545:0.012315:0.005330:0.004893:0.005521:0.012411:0.011507:0.006331:0.003656:0.011545:0.012315:0.005330:0.004893:0.006331:0.005521:0.012315:0.012950:0.006331:0.017857:0.012315:0.011545:0.006331:0.005330:0.004893:0.012411:0.005850:0.005330:0.004893:0.012257:0.011545:0.003656:0.003656:0.012989:0.005521:0.012315:0.011545:0.005330:0.004893:0.012950:0.011545:0.013181:0.005330
adults with PH1 ALL.:@0.084251:0.385781:0.263090:0.385781:0.263090:0.370025:0.084251:0.370025:0.012950:0.012989:0.011507:0.003656:0.006331:0.007274:0.005138:0.015798:0.003656:0.006331:0.011545:0.005138:0.011199:0.012950:0.010468:0.005138:0.014047:0.008698:0.008698:0.005330
16:@0.262877:0.380161:0.275195:0.380161:0.275195:0.370976:0.262877:0.370976:0.006103:0.006215
Allogeneic  stem-cell transplantation  is :@0.102424:0.401854:0.480482:0.401854:0.480482:0.386098:0.102424:0.386098:0.014239:0.003848:0.003848:0.012604:0.012950:0.012508:0.011738:0.012508:0.003848:0.012450:0.005330:0.006793:0.007466:0.006523:0.012508:0.018049:0.006388:0.012450:0.012508:0.003848:0.003848:0.012142:0.006523:0.005792:0.013143:0.011738:0.007466:0.013123:0.003848:0.013143:0.011738:0.006523:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.006794:0.003848:0.007466:0.005330
an important  post-remission strategy  for :@0.084240:0.417927:0.480485:0.417927:0.480485:0.402171:0.084240:0.402171:0.013143:0.011738:0.011430:0.003848:0.018049:0.013123:0.012604:0.005792:0.006523:0.013143:0.011738:0.006523:0.005330:0.006083:0.013123:0.012604:0.007466:0.006523:0.006388:0.005711:0.012508:0.018049:0.003848:0.007466:0.007466:0.003848:0.012604:0.011738:0.011430:0.007466:0.006523:0.005792:0.013143:0.006523:0.012508:0.012950:0.010314:0.005330:0.006088:0.006042:0.012604:0.005792:0.005330
certain patients with adverse biological :@0.084240:0.434001:0.480480:0.434001:0.480480:0.418245:0.084240:0.418245:0.012450:0.012508:0.005792:0.006523:0.013143:0.003848:0.011738:0.011103:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.011103:0.015990:0.003848:0.006523:0.011738:0.011103:0.013143:0.013181:0.010660:0.012508:0.005792:0.007466:0.012508:0.011103:0.013123:0.003848:0.012604:0.003848:0.012604:0.012950:0.003848:0.012450:0.013143:0.003848:0.005330
factors (hyperleukocytosis, BCR/ABL, MLL) :@0.084240:0.450074:0.480476:0.450074:0.480476:0.434318:0.084240:0.434318:0.006042:0.013143:0.012450:0.006523:0.012604:0.005792:0.007466:0.007047:0.007100:0.011738:0.010314:0.013123:0.012508:0.005792:0.003848:0.012508:0.011699:0.009660:0.012604:0.012450:0.010314:0.006523:0.012604:0.007466:0.003848:0.007466:0.005330:0.007050:0.011045:0.015644:0.011680:0.008409:0.014239:0.011045:0.008890:0.005330:0.007047:0.017684:0.008890:0.008890:0.007100:0.005330
and can be an effective salvage modal-:@0.084240:0.466147:0.475144:0.466147:0.475144:0.450392:0.084240:0.450392:0.013143:0.011738:0.013181:0.006820:0.012450:0.013143:0.011738:0.006818:0.013123:0.012508:0.006820:0.013143:0.011738:0.006820:0.012508:0.006096:0.006042:0.012508:0.012450:0.006523:0.003848:0.010660:0.012508:0.006820:0.007466:0.013143:0.003848:0.010674:0.013143:0.012950:0.012508:0.006818:0.018049:0.012604:0.013181:0.013143:0.003848:0.006388
ity for those who suffer disease recurrence. :@0.084240:0.482221:0.480499:0.482221:0.480499:0.466465:0.084240:0.466465:0.003848:0.006523:0.010314:0.004426:0.006042:0.012604:0.005792:0.004408:0.006523:0.011738:0.012604:0.007466:0.012508:0.004412:0.015990:0.011738:0.012604:0.004414:0.007466:0.011699:0.006100:0.006042:0.012508:0.005792:0.004412:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012519:0.004426:0.005713:0.012508:0.012450:0.011699:0.005792:0.005703:0.012508:0.011738:0.012450:0.012508:0.005330:0.005330
However, this intense modality is reserved :@0.084240:0.498294:0.480466:0.498294:0.480466:0.482538:0.084240:0.482538:0.013143:0.012604:0.015990:0.012508:0.010660:0.012508:0.003768:0.005330:0.007062:0.006523:0.011738:0.003848:0.007466:0.007062:0.003848:0.011738:0.006523:0.012508:0.011738:0.007466:0.012508:0.007062:0.018049:0.012604:0.013181:0.013143:0.003848:0.003848:0.006523:0.010314:0.007062:0.003848:0.007466:0.007074:0.005713:0.012508:0.007466:0.012508:0.005792:0.010660:0.012508:0.013181:0.005330
for those who have HLA-identical donors :@0.084240:0.514368:0.480491:0.514368:0.480491:0.498612:0.084240:0.498612:0.006042:0.012604:0.005792:0.008024:0.006523:0.011738:0.012604:0.007466:0.012508:0.008024:0.015990:0.011738:0.012604:0.008024:0.011738:0.013143:0.010660:0.012508:0.008024:0.013143:0.008890:0.014239:0.006388:0.003848:0.013181:0.012508:0.011738:0.006523:0.003848:0.012450:0.013143:0.003848:0.008036:0.013181:0.012604:0.011738:0.012604:0.005792:0.007466:0.005330
and few comorbidities. Despite these as-:@0.084240:0.530441:0.475151:0.530441:0.475151:0.514685:0.084240:0.514685:0.013143:0.011738:0.013181:0.007820:0.006042:0.012508:0.015990:0.007818:0.012450:0.012604:0.018049:0.012604:0.005792:0.013123:0.003848:0.013181:0.003848:0.006523:0.003848:0.012508:0.007466:0.005330:0.007832:0.014316:0.012508:0.007466:0.013123:0.003848:0.006523:0.012508:0.007818:0.006523:0.011738:0.012508:0.007466:0.012508:0.007814:0.013143:0.007466:0.006388
pects,  procedure-related  mortality of  15-:@0.084240:0.546515:0.475159:0.546515:0.475159:0.530759:0.084240:0.530759:0.013123:0.012508:0.012450:0.006523:0.007466:0.005330:0.005330:0.002969:0.013123:0.005713:0.012604:0.012450:0.012508:0.013181:0.011699:0.005713:0.012508:0.006388:0.005711:0.012508:0.003848:0.013143:0.006523:0.012508:0.013181:0.005330:0.002973:0.018049:0.012604:0.005792:0.006523:0.013143:0.003848:0.003848:0.006523:0.010314:0.008313:0.012604:0.006042:0.005330:0.002965:0.010660:0.010660:0.006388
25% reduces the overall success of this :@0.084240:0.562588:0.480497:0.562588:0.480497:0.546832:0.084240:0.546832:0.010660:0.010660:0.014913:0.011045:0.005713:0.012508:0.013181:0.011699:0.012450:0.012508:0.007466:0.011045:0.006523:0.011738:0.012508:0.011045:0.012604:0.010660:0.012508:0.005792:0.013143:0.003848:0.003848:0.011045:0.007466:0.011699:0.012450:0.012450:0.012508:0.007466:0.007466:0.011045:0.012604:0.006042:0.011045:0.006523:0.011738:0.003848:0.007466:0.005330
strategy.  These options should also  be :@0.084240:0.578662:0.480469:0.578661:0.480469:0.562905:0.084240:0.562906:0.007466:0.006523:0.005792:0.013143:0.006523:0.012508:0.012950:0.010314:0.005330:0.012428:0.010872:0.008197:0.011738:0.012508:0.007466:0.012508:0.010872:0.012604:0.013123:0.006523:0.003848:0.012604:0.011738:0.007466:0.010872:0.007466:0.011738:0.012604:0.011699:0.003848:0.013181:0.010872:0.013143:0.003848:0.007466:0.012604:0.005330:0.005553:0.013123:0.012508:0.160635
17:@0.164782:0.573042:0.177212:0.573042:0.177212:0.563856:0.164782:0.563856:0.006215:0.006215
considered for patients with detectable :@0.084237:0.594734:0.480502:0.594734:0.480502:0.578978:0.084237:0.578978:0.012450:0.012604:0.011738:0.007466:0.003848:0.013181:0.012508:0.005711:0.012508:0.013181:0.010506:0.006042:0.012604:0.005782:0.010506:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.010506:0.015990:0.003848:0.006523:0.011738:0.010506:0.013181:0.012508:0.006523:0.012508:0.012450:0.006523:0.013143:0.013123:0.003848:0.012508:0.005330
minimal  residual disease  (MRD) in remis-:@0.084237:0.610808:0.475114:0.610808:0.475114:0.595052:0.084237:0.595052:0.018049:0.003848:0.011738:0.003848:0.018049:0.013143:0.003848:0.005330:0.004555:0.005713:0.012508:0.007466:0.003848:0.013181:0.011699:0.013143:0.003848:0.009871:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.004557:0.007100:0.017684:0.011680:0.014316:0.007100:0.009871:0.003848:0.011738:0.009871:0.005713:0.012508:0.018049:0.003848:0.007466:0.006388
sion following induction therapy.:@0.084237:0.626881:0.385458:0.626881:0.385458:0.611125:0.084237:0.611125:0.007466:0.003848:0.012604:0.011738:0.005330:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.003848:0.011738:0.012950:0.005330:0.003848:0.011738:0.013181:0.011699:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330
CONCLUSION:@0.084242:0.659674:0.239464:0.659674:0.239464:0.640078:0.084242:0.640078:0.018344:0.019756:0.017404:0.018344:0.010348:0.015052:0.012230:0.006585:0.019756:0.017404
Thus, the relevant points in patients with :@0.084242:0.678041:0.480459:0.678041:0.480459:0.662285:0.084242:0.662285:0.008197:0.011738:0.011699:0.007466:0.005330:0.009198:0.006523:0.011738:0.012508:0.009198:0.005711:0.012508:0.003848:0.012508:0.010660:0.013143:0.011738:0.006523:0.009198:0.013123:0.012604:0.003848:0.011738:0.006523:0.007466:0.009198:0.003848:0.011738:0.009198:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.009198:0.015990:0.003848:0.006523:0.011738:0.005330
acute leukaemia remain early diagnosis :@0.084242:0.694114:0.480478:0.694114:0.480478:0.678358:0.084242:0.678358:0.013143:0.012450:0.011699:0.006523:0.012508:0.009833:0.003848:0.012508:0.011699:0.009660:0.013143:0.012508:0.018049:0.003848:0.013143:0.009833:0.005711:0.012508:0.018049:0.013143:0.003848:0.011738:0.009833:0.012508:0.013143:0.005792:0.003848:0.010314:0.009833:0.013181:0.003848:0.013143:0.012950:0.011738:0.012604:0.007466:0.003848:0.007466:0.005330
in patients with unexplained cytopaenia, :@0.084242:0.710188:0.480478:0.710188:0.480478:0.694432:0.084242:0.694432:0.003848:0.011738:0.007764:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.007762:0.015990:0.003848:0.006523:0.011738:0.007762:0.011699:0.011738:0.012508:0.009236:0.013123:0.003848:0.013143:0.003848:0.011738:0.012508:0.013181:0.007764:0.012450:0.010314:0.006523:0.012604:0.013123:0.013143:0.012508:0.011738:0.003848:0.013143:0.005330:0.005330
pyrexia of unknown origin or persistent :@0.084242:0.726261:0.480484:0.726261:0.480484:0.710505:0.084242:0.710505:0.013123:0.010314:0.005717:0.012508:0.009236:0.003848:0.013143:0.012508:0.012604:0.006042:0.012508:0.011699:0.011738:0.009660:0.011738:0.012604:0.015990:0.011738:0.012508:0.012604:0.005792:0.003848:0.012950:0.003848:0.011738:0.012508:0.012604:0.005792:0.012508:0.013123:0.012508:0.005792:0.007466:0.003848:0.007466:0.006523:0.012508:0.011738:0.006523:0.005330
leucocytosis, correction  of  electrolyte, :@0.084242:0.742335:0.480495:0.742335:0.480495:0.726579:0.084242:0.726579:0.003848:0.012508:0.011699:0.012450:0.012604:0.012450:0.010314:0.006523:0.012604:0.007466:0.003848:0.007466:0.005330:0.017434:0.012450:0.012604:0.005792:0.005705:0.012508:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330:0.012088:0.012604:0.006042:0.005330:0.012090:0.012508:0.003848:0.012508:0.012450:0.006523:0.005709:0.012604:0.003848:0.010314:0.006523:0.012508:0.005330:0.005330
metabolic and coagulation abnormali-:@0.084242:0.758408:0.475160:0.758408:0.475160:0.742652:0.084242:0.742652:0.018049:0.012508:0.006523:0.013143:0.013123:0.012604:0.003848:0.003848:0.012450:0.013335:0.013143:0.011738:0.013181:0.013335:0.012450:0.012604:0.013143:0.012950:0.011699:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.013335:0.013143:0.013123:0.011738:0.012604:0.006319:0.018049:0.013143:0.003848:0.003848:0.006388
ties, adequate supportive care with trans-:@0.084242:0.774482:0.475154:0.774482:0.475154:0.758726:0.084242:0.758726:0.006523:0.003848:0.012508:0.007466:0.005330:0.005819:0.013143:0.013181:0.012508:0.013123:0.011699:0.013143:0.006523:0.012508:0.005821:0.007466:0.011699:0.013123:0.013123:0.012604:0.005792:0.006523:0.003848:0.010660:0.012508:0.005821:0.012450:0.013143:0.005715:0.012508:0.005817:0.015990:0.003848:0.006523:0.011738:0.005819:0.006523:0.005792:0.013143:0.011738:0.007466:0.006388
fusion of blood products, prevention of :@0.084242:0.790555:0.480482:0.790555:0.480482:0.774799:0.084242:0.774799:0.006042:0.011699:0.007466:0.003848:0.012604:0.011738:0.011161:0.012604:0.006042:0.011161:0.013123:0.003848:0.012604:0.012604:0.013181:0.011161:0.013123:0.005715:0.012604:0.013181:0.011699:0.012450:0.006523:0.007466:0.005330:0.011161:0.013123:0.005715:0.012508:0.010660:0.012508:0.011738:0.006523:0.003848:0.012604:0.011738:0.011161:0.012604:0.006042:0.005330
infection and aggressive management of :@0.084242:0.806628:0.480484:0.806628:0.480484:0.790872:0.084242:0.790872:0.003848:0.011738:0.006042:0.012508:0.012450:0.006523:0.003848:0.012604:0.011738:0.005832:0.013143:0.011738:0.013181:0.005840:0.013143:0.012950:0.012950:0.005707:0.012508:0.007466:0.007466:0.003848:0.010660:0.012508:0.005850:0.018049:0.013143:0.011738:0.013143:0.012950:0.012508:0.018049:0.012508:0.011738:0.006523:0.005829:0.012604:0.006042:0.005330
sepsis. Following  diagnosis and  initial sta-:@0.084242:0.822702:0.475148:0.822702:0.475148:0.806946:0.084242:0.806946:0.007466:0.012508:0.013123:0.007466:0.003848:0.007466:0.005330:0.008467:0.009333:0.012604:0.003848:0.003848:0.012604:0.015990:0.003848:0.011738:0.012950:0.005330:0.003123:0.013181:0.003848:0.013143:0.012950:0.011738:0.012604:0.007466:0.003848:0.007466:0.008467:0.013143:0.011738:0.013181:0.005330:0.003127:0.003848:0.011738:0.003848:0.006523:0.003848:0.013143:0.003848:0.008467:0.007466:0.006523:0.013143:0.006388
bilisation of the patient, this group should :@0.084242:0.838921:0.480509:0.838921:0.480509:0.823165:0.084242:0.823165:0.013123:0.003848:0.003848:0.003848:0.007466:0.013143:0.006523:0.003848:0.012604:0.011738:0.007100:0.012604:0.006042:0.007100:0.006523:0.011738:0.012508:0.007100:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.005330:0.007091:0.006523:0.011738:0.003848:0.007466:0.007100:0.012950:0.005713:0.012604:0.011699:0.013123:0.007100:0.007466:0.011738:0.012604:0.011699:0.003848:0.013181:0.005330
be referred to a clinical haematologist or :@0.084242:0.855140:0.480490:0.855140:0.480490:0.839384:0.084242:0.839384:0.013123:0.012508:0.006754:0.005713:0.012508:0.006042:0.012508:0.005792:0.005709:0.012508:0.013181:0.006754:0.006523:0.012604:0.006754:0.013143:0.006754:0.012450:0.003848:0.003848:0.011738:0.003848:0.012450:0.013143:0.003848:0.006769:0.011738:0.013143:0.012508:0.018049:0.013143:0.006523:0.012604:0.003848:0.012604:0.012950:0.003848:0.007466:0.006523:0.006754:0.012604:0.005792:0.005330
medical oncologist with experience in the :@0.084242:0.871359:0.480492:0.871359:0.480492:0.855603:0.084242:0.855603:0.018049:0.012508:0.013181:0.003848:0.012450:0.013143:0.003848:0.005330:0.012604:0.011738:0.012450:0.012604:0.003848:0.012592:0.012950:0.003848:0.007466:0.006523:0.005319:0.015990:0.003848:0.006523:0.011738:0.005319:0.012508:0.009236:0.013123:0.012508:0.005792:0.003848:0.012508:0.011738:0.012450:0.012508:0.005309:0.003848:0.011738:0.005319:0.006523:0.011738:0.012508:0.005330
treatment of these diseases. Delays in spe-:@0.084242:0.887578:0.475156:0.887578:0.475156:0.871822:0.084242:0.871822:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.004776:0.012604:0.006042:0.004778:0.006523:0.011738:0.012508:0.007466:0.012508:0.004791:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.007466:0.005330:0.004791:0.014316:0.012508:0.003848:0.013143:0.010314:0.007466:0.004791:0.003848:0.011738:0.004791:0.007466:0.013123:0.012508:0.006388
cific  therapy  lead  to  complications  and :@0.084242:0.903797:0.480484:0.903797:0.480484:0.888041:0.084242:0.888041:0.012450:0.003848:0.004686:0.004686:0.012450:0.005330:0.004287:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.004291:0.003848:0.012508:0.013143:0.013181:0.005330:0.004291:0.006523:0.012604:0.005330:0.004281:0.012450:0.012604:0.018049:0.013123:0.003848:0.003848:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.004287:0.013143:0.011738:0.013181:0.005330
decreased survival of  patients who  may :@0.084242:0.920016:0.480474:0.920016:0.480474:0.904260:0.084242:0.904260:0.013181:0.012508:0.012450:0.005711:0.012508:0.013143:0.007466:0.012508:0.013181:0.009159:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.009159:0.012604:0.006042:0.005330:0.003818:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.009159:0.015990:0.011738:0.012604:0.005330:0.003818:0.018049:0.013143:0.010314:0.005330
otherwise have a curable disease.:@0.084242:0.936235:0.403743:0.936235:0.403743:0.920479:0.084242:0.920479:0.012604:0.006523:0.011738:0.012508:0.005792:0.015990:0.003848:0.007466:0.012508:0.005330:0.011738:0.013143:0.010660:0.012508:0.005330:0.013143:0.005330:0.012450:0.011699:0.005792:0.013143:0.013123:0.003848:0.012508:0.005330:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330
REFERENCES:@0.523643:0.093219:0.634479:0.093219:0.634479:0.077185:0.523643:0.077185:0.011161:0.010006:0.009236:0.010006:0.011161:0.010006:0.014239:0.015009:0.010006:0.010006
1. :@0.523636:0.109976:0.542588:0.109976:0.542588:0.095971:0.523636:0.095971:0.009476:0.004738:0.004738
 Shai Izraeli. Leukaemia – a developmental :@0.559983:0.109976:0.919260:0.109976:0.919260:0.095971:0.559983:0.095971:0.000000:0.008518:0.010434:0.011682:0.003421:0.005884:0.003866:0.007269:0.005148:0.011682:0.011118:0.003421:0.003421:0.004738:0.005884:0.007902:0.011118:0.010399:0.008586:0.011682:0.011118:0.016044:0.003421:0.011682:0.005884:0.008552:0.005884:0.011682:0.005884:0.011716:0.011118:0.009476:0.011118:0.003421:0.011203:0.011665:0.016044:0.011118:0.010434:0.005798:0.011682:0.003421:0.004738
perspective. :@0.559983:0.124110:0.667689:0.124110:0.667689:0.110105:0.559983:0.110105:0.011665:0.011118:0.005148:0.006636:0.011665:0.011118:0.011067:0.005798:0.003421:0.009476:0.011118:0.004738:0.004738
British Journal of Haematology:@0.665602:0.124110:0.909811:0.124110:0.909811:0.110105:0.665602:0.110105:0.009818:0.005148:0.003421:0.005798:0.003421:0.006636:0.010434:0.002639:0.008244:0.011203:0.010399:0.005148:0.010434:0.011682:0.003421:0.002636:0.011203:0.005371:0.002637:0.011682:0.011682:0.011118:0.016044:0.011682:0.005798:0.011203:0.003421:0.011203:0.011511:0.009168
. :@0.909811:0.124110:0.919287:0.124110:0.919287:0.110105:0.909811:0.110105:0.004738:0.004738
2004;126:3-10.:@0.559983:0.138245:0.674633:0.138245:0.674633:0.124240:0.559983:0.124240:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.004738:0.009476:0.005679:0.009476:0.009476:0.004738
2. :@0.523636:0.152380:0.542588:0.152380:0.542588:0.138374:0.523636:0.138374:0.009476:0.004738:0.004738
  PDQ Adult Treatment Editorial Board. Adult :@0.559983:0.152380:0.919297:0.152380:0.919297:0.138374:0.559983:0.138374:0.004738:-0.004738:0.010126:0.012726:0.014898:0.005166:0.012657:0.011716:0.010399:0.003421:0.005798:0.005166:0.006773:0.005077:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.005155:0.009168:0.011716:0.003421:0.005798:0.011203:0.005148:0.003421:0.011682:0.003421:0.005166:0.009818:0.011203:0.011682:0.005046:0.011716:0.004738:0.005166:0.012657:0.011716:0.010399:0.003421:0.005798:0.004738
acute lymphoblastic leukemia treatment :@0.559983:0.166514:0.919292:0.166514:0.919292:0.152509:0.559983:0.152509:0.011682:0.011067:0.010399:0.005798:0.011118:0.010074:0.003421:0.009168:0.016044:0.011665:0.010434:0.011203:0.011665:0.003421:0.011682:0.006636:0.005798:0.003421:0.011067:0.010074:0.003421:0.011118:0.010399:0.008586:0.011118:0.016044:0.003421:0.011682:0.010074:0.005798:0.005078:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.004738
(PDQ®): Health Professional Version. PDQ :@0.559983:0.180649:0.919294:0.180649:0.919294:0.166644:0.559983:0.166644:0.006312:0.010126:0.012726:0.014898:0.012777:0.006312:0.004738:0.008843:0.011682:0.011118:0.011682:0.003421:0.005798:0.010434:0.008843:0.010126:0.005075:0.011203:0.005371:0.011118:0.006636:0.006636:0.003421:0.011203:0.010434:0.011682:0.003421:0.008843:0.010281:0.011118:0.005148:0.006636:0.003421:0.011203:0.010434:0.004738:0.008966:0.010126:0.012726:0.014898:0.004738
 :@0.867861:0.180649:0.872650:0.180649:0.872650:0.166397:0.867861:0.166397:0.004789
Cancer Information Summaries [Internet]. :@0.560000:0.194784:0.919309:0.194784:0.919309:0.180778:0.560000:0.180778:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.008775:0.003866:0.010434:0.005371:0.011203:0.005615:0.016044:0.011682:0.005798:0.003421:0.011203:0.010434:0.008775:0.008518:0.010399:0.016044:0.016044:0.011682:0.005148:0.003421:0.011118:0.006636:0.008775:0.006004:0.003866:0.010434:0.005798:0.011118:0.005501:0.010434:0.011118:0.005798:0.006004:0.004738:0.004738
Bethesda: National Cancer Institute (US); :@0.560000:0.208918:0.919294:0.208918:0.919294:0.194913:0.560000:0.194913:0.009818:0.011118:0.005798:0.010434:0.011118:0.006636:0.011716:0.011682:0.004738:0.009373:0.012657:0.011682:0.005798:0.003421:0.011203:0.010434:0.011682:0.003421:0.009373:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.009373:0.003866:0.010434:0.006636:0.005798:0.003421:0.005798:0.010399:0.005798:0.011118:0.009373:0.006312:0.011203:0.008518:0.006312:0.004738:0.004738
2002-2018. Accessed Feb 2018.:@0.560000:0.223053:0.816172:0.223053:0.816172:0.209048:0.560000:0.209048:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738:0.004738:0.012657:0.011067:0.011067:0.011118:0.006636:0.006636:0.011118:0.011716:0.004738:0.008296:0.011118:0.011665:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738
3. :@0.523653:0.237187:0.542605:0.237187:0.542605:0.223182:0.523653:0.223182:0.009476:0.004738:0.004738
  Leonard JP, Martin P, Roboz GJ.  Practical :@0.560000:0.237187:0.919297:0.237187:0.919297:0.223182:0.560000:0.223182:0.004738:-0.004738:0.007902:0.011118:0.011203:0.010434:0.011682:0.005037:0.011716:0.007748:0.008244:0.008015:0.004738:0.007748:0.015719:0.011682:0.005148:0.005798:0.003421:0.010434:0.007748:0.008017:0.004738:0.007748:0.010382:0.011203:0.011665:0.011203:0.007259:0.007748:0.014915:0.008244:0.004738:0.004738:0.003010:0.010126:0.005148:0.011682:0.011067:0.005798:0.003421:0.011067:0.011682:0.003421:0.004738
Implications  of the 2016  Revision of the :@0.560000:0.251322:0.919306:0.251322:0.919306:0.237317:0.560000:0.237317:0.003866:0.016044:0.011665:0.003421:0.003421:0.011067:0.011682:0.005798:0.003421:0.011203:0.010434:0.006636:0.004738:0.005947:0.011203:0.005371:0.010673:0.005798:0.010434:0.011118:0.010673:0.009476:0.009476:0.009476:0.009476:0.004738:0.005952:0.010382:0.011118:0.009476:0.003421:0.006636:0.003421:0.011203:0.010434:0.010673:0.011203:0.005371:0.010673:0.005798:0.010434:0.011118:0.004738
World Health Organization classification of :@0.560000:0.265457:0.919311:0.265457:0.919311:0.251451:0.560000:0.251451:0.015635:0.011203:0.005148:0.003421:0.011716:0.006260:0.011682:0.011118:0.011682:0.003421:0.005798:0.010434:0.006264:0.014864:0.005164:0.011511:0.011682:0.010434:0.003421:0.007269:0.011682:0.005798:0.003421:0.011203:0.010434:0.006257:0.011067:0.003421:0.011682:0.006636:0.006636:0.003421:0.004165:0.004177:0.011067:0.011682:0.005798:0.003421:0.011203:0.010434:0.006265:0.011203:0.005371:0.004738
lymphoid and  myeloid  neoplasms  and :@0.560000:0.279591:0.919277:0.279591:0.919277:0.265586:0.560000:0.265586:0.003421:0.009168:0.016044:0.011665:0.010434:0.011203:0.003421:0.011716:0.013718:0.011682:0.010434:0.011716:0.004738:0.008980:0.016044:0.009168:0.011118:0.003421:0.011203:0.003421:0.011716:0.004738:0.008980:0.010434:0.011118:0.011203:0.011665:0.003421:0.011682:0.006636:0.016044:0.006636:0.004738:0.008980:0.011682:0.010434:0.011716:0.004738
acute leukemia. J :@0.560000:0.293726:0.712904:0.293726:0.712904:0.279721:0.560000:0.279721:0.011682:0.011067:0.010399:0.005798:0.011118:0.004661:0.003421:0.011118:0.010399:0.008586:0.011118:0.016044:0.003421:0.011682:0.004738:0.004669:0.008244:0.004738
Clin Oncol.:@0.712836:0.293726:0.804412:0.293726:0.804412:0.279721:0.712836:0.279721:0.013906:0.003421:0.003421:0.010434:0.004669:0.014864:0.010434:0.011067:0.011203:0.003421:0.004738
 2017 Aug 10; :@0.804412:0.293726:0.919308:0.293726:0.919308:0.279721:0.804412:0.279721:0.004669:0.009476:0.009476:0.009476:0.009476:0.004669:0.012657:0.010399:0.011511:0.004658:0.009476:0.009476:0.004738:0.004738
35(23):2708-2715.:@0.560000:0.307861:0.701487:0.307861:0.701487:0.293855:0.560000:0.293855:0.009476:0.009476:0.006312:0.009476:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738
4. :@0.523653:0.321995:0.542605:0.321995:0.542605:0.307990:0.523653:0.307990:0.009476:0.004738:0.004738
  Haferlach T, Bacher U, Kern W, :@0.560000:0.321995:0.833570:0.321995:0.833570:0.307990:0.560000:0.307990:0.004738:-0.004738:0.011682:0.011682:0.005371:0.011118:0.005148:0.003421:0.011682:0.011067:0.010434:0.009048:0.005537:0.004738:0.009048:0.009818:0.011682:0.011067:0.010434:0.011118:0.005148:0.009048:0.011203:0.004738:0.009048:0.010109:0.011118:0.005499:0.010434:0.009048:0.014607:0.004738:0.004738
et al:@0.837881:0.321995:0.878948:0.321995:0.878948:0.307990:0.837881:0.307990:0.011118:0.005798:0.009048:0.011682:0.003421
. Di-:@0.878948:0.321995:0.914559:0.321995:0.914559:0.307990:0.878948:0.307990:0.004738:0.009048:0.012726:0.003421:0.005679
agnostic pathways  in acute leukemias: a :@0.560000:0.336130:0.919287:0.336130:0.919287:0.322125:0.560000:0.322125:0.011682:0.011511:0.010434:0.011203:0.006636:0.005798:0.003421:0.011067:0.007748:0.011665:0.011682:0.005798:0.010434:0.014214:0.011682:0.009168:0.006636:0.004738:0.003021:0.003421:0.010434:0.007748:0.011682:0.011067:0.010399:0.005798:0.011118:0.007748:0.003421:0.011118:0.010399:0.008586:0.011118:0.016044:0.003421:0.011682:0.006636:0.004738:0.007748:0.011682:0.004738
proposal for a multimodal approach. :@0.560000:0.350265:0.879259:0.350265:0.879259:0.336259:0.560000:0.336259:0.011665:0.005080:0.011203:0.011665:0.011203:0.006636:0.011682:0.003421:0.006551:0.005371:0.011203:0.005148:0.006536:0.011682:0.006551:0.016044:0.010399:0.003421:0.005798:0.003421:0.016044:0.011203:0.011716:0.011682:0.003421:0.006551:0.011682:0.011665:0.011665:0.005085:0.011203:0.011682:0.011067:0.010434:0.004738:0.004738
Ann :@0.881049:0.350265:0.919311:0.350265:0.919311:0.336259:0.881049:0.336259:0.012657:0.010434:0.010434:0.004738
Hematol:@0.560000:0.364399:0.630949:0.364399:0.630949:0.350394:0.560000:0.350394:0.011682:0.011118:0.016044:0.011682:0.005798:0.011203:0.003421
. 2007;86:311-327.:@0.630949:0.364399:0.774027:0.364399:0.774027:0.350394:0.630949:0.350394:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
5. :@0.523653:0.378534:0.542605:0.378534:0.542605:0.364528:0.523653:0.364528:0.009476:0.004738:0.004738
  Mrózek  K,  Bloomfield  CD.  Clinical  signifi-:@0.560000:0.378534:0.914559:0.378534:0.914559:0.364528:0.560000:0.364528:0.004738:-0.004738:0.015719:0.005148:0.011203:0.007269:0.011118:0.008586:0.004738:0.005814:0.010109:0.004738:0.004738:0.005822:0.009818:0.003421:0.011203:0.011203:0.016044:0.004165:0.004165:0.011118:0.003421:0.011716:0.004738:0.005827:0.013906:0.012726:0.004738:0.004738:0.005827:0.013906:0.003421:0.003421:0.010434:0.003421:0.011067:0.011682:0.003421:0.004738:0.005841:0.006636:0.003421:0.011511:0.010434:0.003421:0.004165:0.004165:0.005679
cance of the most common chromosome :@0.560000:0.392668:0.919314:0.392668:0.919314:0.378663:0.560000:0.378663:0.011067:0.011682:0.010434:0.011067:0.011118:0.005918:0.011203:0.005371:0.005918:0.005798:0.010434:0.011118:0.005918:0.016044:0.011203:0.006636:0.005798:0.005918:0.011067:0.011203:0.016044:0.016044:0.011203:0.010434:0.005910:0.011067:0.010434:0.005075:0.011203:0.016044:0.011203:0.006636:0.011203:0.016044:0.011118:0.004738
translocations in adult acute myeloid leu-:@0.560000:0.406803:0.914556:0.406803:0.914556:0.392798:0.560000:0.392798:0.005798:0.005148:0.011682:0.010434:0.006636:0.003421:0.011203:0.011067:0.011682:0.005798:0.003421:0.011203:0.010434:0.006636:0.007269:0.003421:0.010434:0.007269:0.011682:0.011716:0.010399:0.003421:0.005798:0.007269:0.011682:0.011067:0.010399:0.005798:0.011118:0.007269:0.016044:0.009168:0.011118:0.003421:0.011203:0.003421:0.011716:0.007269:0.003421:0.011118:0.010399:0.005679
kemia. :@0.560000:0.420938:0.620327:0.420938:0.620327:0.406932:0.560000:0.406932:0.008586:0.011118:0.016044:0.003421:0.011682:0.004738:0.004738
Journal of the National Cancer Insti-:@0.619762:0.420938:0.914573:0.420938:0.914573:0.406932:0.619762:0.406932:0.008244:0.011203:0.010399:0.005148:0.010434:0.011682:0.003421:0.004173:0.011203:0.005371:0.004173:0.005798:0.010434:0.011118:0.004173:0.012657:0.011682:0.005798:0.003421:0.011203:0.010434:0.011682:0.003421:0.004173:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.004173:0.003866:0.010434:0.006636:0.005798:0.003421:0.005679
tute Monographs. :@0.560000:0.435072:0.712947:0.435072:0.712947:0.421067:0.560000:0.421067:0.005798:0.010399:0.005798:0.011118:0.004738:0.015719:0.011203:0.010434:0.011203:0.011511:0.005148:0.011682:0.011648:0.010434:0.006636:0.004738:0.004738
2008 39:52-57.:@0.712947:0.435072:0.827615:0.435072:0.827615:0.421067:0.712947:0.421067:0.009476:0.009476:0.009476:0.009476:0.004755:0.009476:0.009476:0.004738:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
;:@0.750867:0.435072:0.755605:0.435072:0.755605:0.421067:0.750867:0.421067:0.004738
6. :@0.523670:0.448913:0.542622:0.448913:0.542622:0.434908:0.523670:0.434908:0.009476:0.004738:0.004738
  Bienz M, Ludwig, M, Mueller BU, :@0.560017:0.448913:0.832626:0.448913:0.832626:0.434908:0.560017:0.434908:0.004738:-0.004738:0.009818:0.003421:0.011118:0.010434:0.007269:0.006979:0.015719:0.004738:0.006979:0.007902:0.010399:0.011716:0.014214:0.003421:0.011511:0.004738:0.006979:0.015719:0.004738:0.006979:0.015719:0.010399:0.011118:0.003421:0.003421:0.011118:0.005148:0.006979:0.009818:0.011203:0.004738:0.004738
et al:@0.834867:0.448913:0.873865:0.448913:0.873865:0.434908:0.834867:0.434908:0.011118:0.005798:0.006979:0.011682:0.003421
. Risk :@0.873865:0.448913:0.919345:0.448913:0.919345:0.434908:0.873865:0.434908:0.004738:0.006979:0.010382:0.003421:0.006636:0.008586:0.004738
assessment in patients with  acute  my-:@0.560017:0.462754:0.914587:0.462754:0.914587:0.448748:0.560017:0.448748:0.011682:0.006636:0.006636:0.011118:0.006636:0.006636:0.016044:0.011118:0.010434:0.005798:0.013324:0.003421:0.010434:0.013324:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.013324:0.014214:0.003421:0.005798:0.010434:0.004738:0.008578:0.011682:0.011067:0.010399:0.005798:0.011118:0.004738:0.008574:0.016044:0.009168:0.005679
eloid  leukemia  and  a  normal karyotype. :@0.560017:0.476594:0.919330:0.476594:0.919330:0.462589:0.560017:0.462589:0.011118:0.003421:0.011203:0.003421:0.011716:0.004738:0.004404:0.003421:0.011118:0.010399:0.008586:0.011118:0.016044:0.003421:0.011682:0.004738:0.004404:0.011682:0.010434:0.011716:0.004738:0.004401:0.011682:0.004738:0.004404:0.010434:0.011203:0.005615:0.016044:0.011682:0.003421:0.009151:0.008586:0.011682:0.005148:0.009168:0.011203:0.005798:0.009168:0.011665:0.011118:0.004738:0.004738
Clinical  Cancer Research:@0.560017:0.490435:0.780526:0.490435:0.780526:0.476430:0.560017:0.476430:0.013906:0.003421:0.003421:0.010434:0.003421:0.011067:0.011682:0.003421:0.004738:0.004669:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.009390:0.010382:0.011118:0.006636:0.011118:0.011682:0.005148:0.011067:0.010434
. 2005  February :@0.780526:0.490435:0.919330:0.490435:0.919330:0.476430:0.780526:0.476430:0.004738:0.009390:0.009476:0.009476:0.009476:0.009476:0.004738:0.004671:0.008296:0.011118:0.011665:0.005148:0.010399:0.011682:0.005148:0.009168:0.004738
15;11:1416-1424.:@0.560017:0.504276:0.693619:0.504276:0.693619:0.490270:0.560017:0.490270:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738
7. :@0.523670:0.518116:0.542622:0.518116:0.542622:0.504111:0.523670:0.504111:0.009479:0.004734:0.004738
 Robak T, Wierzbowska A. Current and emerg-:@0.560015:0.518116:0.914594:0.518116:0.914594:0.504111:0.560015:0.504111:0.000000:0.010040:0.010861:0.011323:0.011340:0.008244:0.003592:0.005195:0.004396:0.003592:0.016177:0.003079:0.010776:0.004806:0.006927:0.011323:0.010861:0.013872:0.006294:0.008244:0.011340:0.003592:0.012315:0.004396:0.003592:0.013564:0.010057:0.004806:0.004736:0.010776:0.010092:0.005456:0.003592:0.011340:0.010092:0.011374:0.003592:0.010776:0.015702:0.010776:0.004820:0.011169:0.005679
ing therapies for acute myeloid leukemia. :@0.560017:0.531957:0.919325:0.531957:0.919325:0.517952:0.560017:0.517952:0.003079:0.010092:0.011169:0.009151:0.005456:0.010092:0.010776:0.004806:0.011340:0.011323:0.003079:0.010776:0.006294:0.009151:0.005029:0.010861:0.004806:0.009151:0.011340:0.010724:0.010057:0.005456:0.010776:0.009151:0.015702:0.008826:0.010776:0.003079:0.010861:0.003079:0.011374:0.009151:0.003079:0.010776:0.010057:0.008244:0.010776:0.015702:0.003079:0.011340:0.004734:0.004738
Clin Ther:@0.560017:0.545797:0.627186:0.545797:0.627186:0.531792:0.560017:0.531792:0.013564:0.003079:0.003079:0.010092:0.004396:0.006944:0.010092:0.010776:0.005148
. 2009;31[Theme Issue]:2349-2370.:@0.626844:0.545797:0.889327:0.545797:0.889327:0.531792:0.626844:0.531792:0.004396:0.004396:0.009134:0.009134:0.009134:0.009134:0.004396:0.009134:0.009134:0.005662:0.006944:0.010092:0.010776:0.015702:0.010776:0.004396:0.003523:0.006294:0.006294:0.010057:0.010776:0.005662:0.004396:0.009134:0.009134:0.009134:0.009134:0.005337:0.009134:0.009134:0.009134:0.009134:0.004738
8. :@0.523670:0.559638:0.542622:0.559638:0.542622:0.545633:0.523670:0.545633:0.009479:0.004734:0.004738
 Estey E. What is the optimal induction strategy :@0.560015:0.559638:0.919366:0.559638:0.919366:0.545633:0.560015:0.545633:0.000000:0.008655:0.006123:0.005285:0.010605:0.008655:0.004156:0.008655:0.004225:0.004156:0.015907:0.009921:0.011169:0.005285:0.004156:0.002908:0.006123:0.004156:0.005285:0.009921:0.010605:0.004156:0.010690:0.011152:0.005285:0.002908:0.015531:0.011169:0.002908:0.004156:0.002908:0.009921:0.011203:0.009886:0.010553:0.005285:0.002908:0.010690:0.009921:0.004156:0.006123:0.005285:0.004635:0.011169:0.005285:0.010605:0.010998:0.009171:0.004738
for older patients? :@0.560017:0.573479:0.710108:0.573479:0.710108:0.559473:0.560017:0.559473:0.004858:0.010690:0.004635:0.006542:0.010690:0.002908:0.011203:0.010605:0.004635:0.006542:0.011152:0.011169:0.005285:0.002908:0.010605:0.009921:0.005285:0.006123:0.009596:0.004738
Best Practice & Research :@0.711904:0.573479:0.919333:0.573479:0.919333:0.559473:0.711904:0.559473:0.009305:0.010605:0.006123:0.005285:0.006541:0.009613:0.004635:0.011169:0.010553:0.005285:0.002908:0.010553:0.010605:0.006542:0.012435:0.006542:0.009869:0.010605:0.006123:0.010605:0.011169:0.004635:0.010553:0.010432:0.004738
Clinical Haematology. :@0.560017:0.587319:0.738740:0.587319:0.738740:0.573314:0.560017:0.573314:0.013393:0.002908:0.002908:0.009921:0.002908:0.010553:0.011169:0.002908:0.004225:0.011169:0.011169:0.010605:0.015531:0.011169:0.005285:0.010690:0.002908:0.010690:0.010998:0.008655:0.004225:0.004738
2011;24:515-522.:@0.738227:0.587319:0.864132:0.587319:0.864132:0.573314:0.738227:0.573314:0.008963:0.008963:0.008963:0.008963:0.004225:0.008963:0.008963:0.004225:0.008963:0.008963:0.008963:0.005166:0.008963:0.008963:0.008963:0.004738
9. :@0.523670:0.601160:0.542622:0.601160:0.542622:0.587155:0.523670:0.587155:0.009476:0.004738:0.004738
  Ravandi F,  Stone  R.  Acute  promyelocytic :@0.560017:0.601160:0.919320:0.601160:0.919320:0.587155:0.560017:0.587155:0.004738:-0.004738:0.010382:0.011682:0.009476:0.011682:0.010434:0.011716:0.003421:0.008450:0.006205:0.004738:0.004738:0.003698:0.008518:0.005798:0.011203:0.010434:0.011118:0.004738:0.003691:0.010382:0.004738:0.004738:0.003696:0.012657:0.011067:0.010399:0.005798:0.011118:0.004738:0.003689:0.011665:0.005078:0.011203:0.016044:0.009168:0.011118:0.003421:0.011203:0.011067:0.009168:0.005798:0.003421:0.011067:0.004738
leukemia: a perspective. :@0.560017:0.615001:0.776969:0.615001:0.776969:0.600995:0.560017:0.600995:0.003421:0.011118:0.010399:0.008586:0.011118:0.016044:0.003421:0.011682:0.004738:0.008518:0.011682:0.008518:0.011665:0.011118:0.005148:0.006636:0.011665:0.011118:0.011067:0.005798:0.003421:0.009476:0.011118:0.004738:0.004738
Clin Lymphoma :@0.780749:0.615001:0.919328:0.615001:0.919328:0.600995:0.780749:0.600995:0.013906:0.003421:0.003421:0.010434:0.008518:0.007902:0.009168:0.016044:0.011665:0.010434:0.011203:0.016044:0.011682:0.004738
Myeloma Leuk. :@0.560017:0.628841:0.690592:0.628841:0.690592:0.614836:0.560017:0.614836:0.015719:0.009168:0.011118:0.003421:0.011203:0.016044:0.011682:0.004738:0.007902:0.011118:0.010399:0.008586:0.004738:0.004738
2017 Sep;17(9):543-544.:@0.690574:0.628841:0.882314:0.628841:0.882314:0.614836:0.690574:0.614836:0.009476:0.009476:0.009476:0.009476:0.004738:0.008518:0.011118:0.011665:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
10.   Barba P, Martino R, Pérez-Simón JA, :@0.523670:0.642682:0.868030:0.642682:0.868030:0.628677:0.523670:0.628677:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.009818:0.011682:0.005148:0.011665:0.011682:0.007280:0.008017:0.004738:0.007269:0.015719:0.011682:0.005148:0.005798:0.003421:0.010434:0.011203:0.007269:0.010382:0.004738:0.007269:0.010126:0.011118:0.005073:0.011118:0.007269:0.005679:0.008518:0.003421:0.016044:0.011203:0.010434:0.007269:0.008244:0.012657:0.004738:0.004738
et al:@0.870562:0.642682:0.909851:0.642682:0.909851:0.628677:0.870562:0.628677:0.011118:0.005798:0.007269:0.011682:0.003421
. :@0.909851:0.642682:0.919326:0.642682:0.919326:0.628677:0.909851:0.628677:0.004738:0.004738
Combination of the Hematopoietic Cell :@0.560017:0.656523:0.919311:0.656523:0.919311:0.642517:0.560017:0.642517:0.013906:0.011203:0.016044:0.011665:0.003421:0.010434:0.011682:0.005798:0.003421:0.011203:0.010434:0.011084:0.011203:0.005371:0.011084:0.005798:0.010434:0.011118:0.011084:0.011682:0.011118:0.016044:0.011682:0.005798:0.011203:0.011665:0.011203:0.003421:0.011118:0.005798:0.003421:0.011067:0.011084:0.013906:0.011118:0.003421:0.003421:0.004738
Transplantation Comorbidity Index and :@0.560017:0.670363:0.919328:0.670363:0.919328:0.656358:0.560017:0.656358:0.006773:0.005148:0.011682:0.010434:0.006636:0.011665:0.003421:0.011682:0.010434:0.005798:0.011682:0.005798:0.003421:0.011203:0.010434:0.015497:0.013906:0.011203:0.016044:0.011203:0.005148:0.011665:0.003421:0.011716:0.003421:0.005798:0.009168:0.015497:0.003866:0.010434:0.011716:0.011118:0.008210:0.015497:0.011682:0.010434:0.011716:0.004738
the European Group for Blood and Marrow :@0.560017:0.684204:0.919328:0.684204:0.919328:0.670199:0.560017:0.670199:0.005798:0.010434:0.011118:0.004538:0.009168:0.010399:0.005077:0.011203:0.011665:0.011118:0.011682:0.010434:0.004541:0.014915:0.005078:0.011203:0.010399:0.011665:0.004541:0.005371:0.011203:0.005148:0.004538:0.009818:0.003421:0.011203:0.011203:0.011716:0.004550:0.011682:0.010434:0.011716:0.004550:0.015719:0.011682:0.005148:0.005075:0.011203:0.014214:0.004738
Transplantation score allows a better strati-:@0.560017:0.698045:0.914582:0.698045:0.914582:0.684039:0.560017:0.684039:0.006773:0.005148:0.011682:0.010434:0.006636:0.011665:0.003421:0.011682:0.010434:0.005798:0.011682:0.005798:0.003421:0.011203:0.010434:0.005234:0.006636:0.011067:0.011203:0.005077:0.011118:0.005234:0.011682:0.003421:0.003421:0.011203:0.014214:0.006636:0.005246:0.011682:0.005234:0.011665:0.011118:0.005798:0.005798:0.011118:0.005148:0.005234:0.006636:0.005798:0.005148:0.011682:0.005798:0.003421:0.005679
fication of high-risk patients undergoing re-:@0.560017:0.711885:0.914573:0.711885:0.914573:0.697880:0.560017:0.697880:0.004165:0.004165:0.011067:0.011682:0.005798:0.003421:0.011203:0.010434:0.004984:0.011203:0.005371:0.004991:0.010434:0.003421:0.011511:0.010434:0.005679:0.005148:0.003421:0.006636:0.008586:0.004993:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.004994:0.010399:0.010434:0.011716:0.011118:0.005162:0.011511:0.011203:0.003421:0.010434:0.011511:0.004983:0.005078:0.011612:0.005679
duced-toxicity  allogeneic  hematopoie- :@0.560017:0.725726:0.919311:0.725726:0.919311:0.711721:0.560017:0.711721:0.012230:0.010913:0.011580:0.011631:0.012230:0.006192:0.006312:0.011716:0.008723:0.003934:0.011580:0.003934:0.006312:0.009681:0.004738:0.005824:0.012195:0.003934:0.003934:0.011716:0.012024:0.011631:0.010947:0.011631:0.003934:0.011580:0.004738:0.005822:0.010947:0.011631:0.016557:0.012195:0.006312:0.011716:0.012178:0.011200:0.003424:0.011116:0.005665:0.004738
tic cell transplantation. :@0.560017:0.739567:0.758821:0.739567:0.758821:0.725561:0.560017:0.725561:0.005798:0.003421:0.011067:0.007389:0.011067:0.011118:0.003421:0.003421:0.007389:0.005798:0.005148:0.011682:0.010434:0.006636:0.011665:0.003421:0.011682:0.010434:0.005798:0.011682:0.005798:0.003421:0.011203:0.010434:0.004738:0.004738
Biol Blood Marrow :@0.761472:0.739567:0.919328:0.739567:0.919328:0.725561:0.761472:0.725561:0.009818:0.003421:0.011203:0.003421:0.007389:0.009818:0.003421:0.011203:0.011203:0.011716:0.007389:0.015719:0.011682:0.005148:0.005148:0.011203:0.014214:0.004738
Transplant.:@0.560017:0.753407:0.648942:0.753407:0.648942:0.739402:0.560017:0.739402:0.007286:0.005148:0.011682:0.010434:0.006636:0.011665:0.003421:0.011682:0.010434:0.005798:0.004738
 2014 Jan;20(1):66-72.:@0.648942:0.753407:0.825528:0.753407:0.825528:0.739402:0.648942:0.739402:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.008244:0.011682:0.010434:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
11.   Authors  PDQ  Adult  Treatment  Editorial :@0.523670:0.767248:0.919340:0.767248:0.919340:0.753243:0.523670:0.753243:0.009479:0.009479:0.004731:0.004738:0.007914:0.000000:0.012486:0.010228:0.005627:0.010263:0.011032:0.004977:0.006465:0.004738:0.012065:0.009955:0.012555:0.014727:0.004738:0.012065:0.012486:0.011545:0.010228:0.003250:0.005627:0.004738:0.012065:0.006602:0.004907:0.010947:0.011511:0.005627:0.015873:0.010947:0.010263:0.005627:0.004738:0.012065:0.008997:0.011545:0.003250:0.005627:0.011032:0.004977:0.003250:0.011511:0.003424:0.004738
Board. Adult acute lymphoblastic leukemia :@0.560017:0.781088:0.919309:0.781088:0.919309:0.767083:0.560017:0.767083:0.009647:0.011032:0.011511:0.004873:0.011545:0.004567:0.005260:0.012486:0.011545:0.010228:0.003250:0.005627:0.005260:0.011511:0.010895:0.010228:0.005627:0.010947:0.005258:0.003250:0.008997:0.015873:0.011494:0.010263:0.011032:0.011494:0.003250:0.011511:0.006465:0.005627:0.003250:0.010895:0.005260:0.003250:0.010947:0.010228:0.008415:0.010947:0.015873:0.003250:0.011684:0.004738
treatment (PDQ®): Health Professional Ver-:@0.560017:0.794929:0.914568:0.794929:0.914568:0.780924:0.560017:0.780924:0.005627:0.004906:0.010947:0.011511:0.005627:0.015873:0.010947:0.010263:0.005627:0.006859:0.006140:0.009955:0.012555:0.014727:0.012606:0.006140:0.004567:0.006859:0.011511:0.010947:0.011511:0.003250:0.005627:0.010263:0.006859:0.009955:0.004906:0.011032:0.005200:0.010947:0.006465:0.006465:0.003250:0.011032:0.010263:0.011511:0.003250:0.006859:0.010110:0.010947:0.004977:0.005679
sion. Source PDQ Cancer Information Sum-:@0.560017:0.808770:0.914633:0.808770:0.914633:0.794764:0.560017:0.794764:0.006465:0.003250:0.011032:0.010263:0.004567:0.005969:0.008347:0.011032:0.010228:0.004856:0.010895:0.010947:0.005969:0.009955:0.012555:0.014727:0.005969:0.013735:0.011511:0.010263:0.010895:0.010947:0.004977:0.005969:0.003695:0.010263:0.005200:0.011032:0.005449:0.015873:0.011511:0.005627:0.003250:0.011032:0.010263:0.005969:0.008347:0.010228:0.015873:0.005679
maries [Internet]. Bethesda: National Can-:@0.560017:0.822904:0.914602:0.822904:0.914602:0.808899:0.560017:0.808899:0.015873:0.011511:0.004977:0.003250:0.010947:0.006465:0.007748:0.005833:0.003695:0.010263:0.005627:0.010947:0.005331:0.010263:0.010947:0.005627:0.005833:0.004567:0.007748:0.009647:0.010947:0.005627:0.010263:0.010947:0.006465:0.011545:0.011511:0.004567:0.007748:0.012486:0.011511:0.005627:0.003250:0.011032:0.010263:0.011511:0.003250:0.007748:0.013735:0.011511:0.010263:0.005679
cer Institute (US); 2002-2018. Accessed Feb :@0.560017:0.837039:0.919296:0.837039:0.919296:0.823034:0.560017:0.823034:0.010895:0.010947:0.004977:0.006773:0.003695:0.010263:0.006465:0.005627:0.003250:0.005627:0.010228:0.005627:0.010947:0.006773:0.006140:0.011032:0.008347:0.006140:0.004567:0.006773:0.009305:0.009305:0.009305:0.009305:0.005508:0.009305:0.009305:0.009305:0.009305:0.004567:0.006773:0.012486:0.010895:0.010895:0.010947:0.006465:0.006465:0.010947:0.011545:0.006773:0.008125:0.010947:0.011667:0.004738
2018.:@0.560017:0.851174:0.601974:0.851174:0.601974:0.837168:0.560017:0.837168:0.009305:0.009305:0.009305:0.009305:0.004738
12.   Ribera JM. Advances in acute lymphoblas-:@0.523670:0.865308:0.914573:0.865308:0.914573:0.851303:0.523670:0.851303:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.010382:0.003421:0.011665:0.011118:0.005148:0.011682:0.004550:0.008244:0.015719:0.004738:0.004539:0.012657:0.011716:0.009476:0.011682:0.010434:0.011067:0.011118:0.006636:0.004550:0.003421:0.010434:0.004550:0.011682:0.011067:0.010399:0.005798:0.011118:0.004541:0.003421:0.009168:0.016044:0.011665:0.010434:0.011203:0.011665:0.003421:0.011682:0.006621:0.005679
tic  leukemia  in  adults. :@0.560017:0.879443:0.753578:0.879443:0.753578:0.865438:0.560017:0.865438:0.005798:0.003421:0.011067:0.004738:0.003429:0.003421:0.011118:0.010399:0.008586:0.011118:0.016044:0.003421:0.011682:0.004738:0.003429:0.003421:0.010434:0.004738:0.003429:0.011682:0.011716:0.010399:0.003421:0.005798:0.006636:0.004738:0.004738
Current  Opinion in :@0.757008:0.879443:0.919320:0.879443:0.919320:0.865438:0.757008:0.865438:0.013906:0.010399:0.005148:0.005148:0.011118:0.010434:0.005798:0.004738:0.003412:0.014864:0.011665:0.003421:0.010434:0.003421:0.011203:0.010434:0.008176:0.003421:0.010434:0.004738
Oncology:@0.560017:0.893578:0.642887:0.893578:0.642887:0.879572:0.560017:0.879572:0.014864:0.010434:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168
. 2011;23:692-699.:@0.642887:0.893578:0.785965:0.893578:0.785965:0.879572:0.642887:0.879572:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
13.   Bassan  R, Hoelzer D. Modern therapy of :@0.523670:0.907712:0.919333:0.907712:0.919333:0.893707:0.523670:0.893707:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.009818:0.011682:0.006636:0.006636:0.011682:0.010434:0.004738:0.004752:0.010382:0.004738:0.009476:0.011682:0.011203:0.011118:0.003421:0.007269:0.011118:0.005148:0.009476:0.012726:0.004738:0.009476:0.015719:0.011203:0.011716:0.011118:0.005499:0.010434:0.009476:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.009476:0.011203:0.005371:0.004738
acute  lymphoblastic leukemia. :@0.560017:0.921847:0.826149:0.921847:0.826149:0.907842:0.560017:0.907842:0.011682:0.011067:0.010399:0.005798:0.011118:0.004738:0.002844:0.003421:0.009168:0.016044:0.011665:0.010434:0.011203:0.011665:0.003421:0.011682:0.006636:0.005798:0.003421:0.011067:0.007594:0.003421:0.011118:0.010399:0.008586:0.011118:0.016044:0.003421:0.011682:0.004738:0.004738
J  Clin On-:@0.829000:0.921847:0.914582:0.921847:0.914582:0.907842:0.829000:0.907842:0.008244:0.004738:0.002848:0.013906:0.003421:0.003421:0.010434:0.007594:0.014864:0.010434:0.005679
col. :@0.560017:0.935981:0.595183:0.935981:0.595183:0.921976:0.560017:0.921976:0.011067:0.011203:0.003421:0.004738:0.004738
2011;29:532-543.:@0.595183:0.935981:0.728786:0.935981:0.728786:0.921976:0.595183:0.921976:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738